MarginsXMarginsX
Home › Markets › Health Care › GNPX

Genprex Inc. (GNPX)

GNPX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.90
-8.65% on the day
Market cap
$2.5M
Nano cap
Revenue · 2024
$0
Prior year not contiguous
Net income · 2024
-$21.1M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1595248/000143774925010311/0001437749-25-010311-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.

Profile

FieldValue
TickerGNPX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001595248
SEC industry codePharmaceutical Preparations
Incorporated inTX

Financials · 2024

LineValue
Revenue$0
Net income-$21.1M
Operating income-$21.2M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$1.6M
Total assets$4.1M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
11.7 months
$15.2M cash at June 30, 2026
Share count, 1 year
+1193.4%
2025-11-13 to 2026-11-09 · +98712.7% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
-$22
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"As a result of its recurring losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding the Company's ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company's ability to continue as a going concern."
10-Q 2026-11-13
Cash and burn$15.2M cash; operating cash flow -$3.9M a quarter.Report 2026-06-30
Shares outstanding1,334,753 (2026-11-09); 2,270,346 a year earlier; 59,434,822 three years earlier. 1y figure adjusted for splits (1-for-22 overall); 3y figure adjusted for splits (1-for-44000 overall).Cover page 2026-11-09
Reverse splits, 3 years3; latest 1-for-22 on 2026-07-16Source 2026-07-16
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2025-11-21
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-07-30
AuditorWithumSmith+Brown, PC, East Brunswick, New Jersey, United StatesPCAOB Form AP 2026-04-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $22 on the open marketSEC Forms 3/4/5 data sets 2026-09-30
Market cap checkThe listing's market cap implies 819,709 shares at the 2026-11-13 price; the latest SEC cover count is 1,334,753 as of 2026-11-09. One of the two share counts is stale.Nasdaq screener and SEC cover page

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$4.4M-$5.1M$15.2MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$4.5M-$3.1M$18.0MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-12-31
Not filed-$3.8M-$4.1M$7.8MNo debt tagsNeeds four quarters10-K 2026-03-30
Q3 2025
2025-09-30
Not filed-$3.8M-$3.2M$1.1MNo debt tagsNeeds four quarters10-Q 2025-11-14
Q2 2025
2025-06-30
Not filed-$4.7M-$3.9M$1.3MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$4.0M-$4.2M$3.5MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2024
2024-12-31
Not filed-$4.3M-$3.9M$1.6MNo debt tags$010-K 2026-03-30
Q3 2024
2024-09-30
Not filed-$4.3M-$2.2M$1.5MNo debt tagsNeeds four quarters10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM S-3
S-32026-06-05
Latest annual report
FORM 10-K
10-K2026-03-30
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-13
Latest current report
FORM 8-K
8-K2026-11-05
Latest proxy
FORM DEF 14A
DEF 14A2026-04-29

Source: SEC EDGAR submissions feed, 492 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.5%
1 month-17.1%
3 months-57.3%
Year to date-94.6%
1 year-97.7%
From 52-week high-97.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
REVBRevelation Biosciences Inc.$3.82-10.43%$2.6M
EOCNEocene Ltd.$2.53+5.86%$2.6M
PRFXPRF Technologies Ltd.$0.6948-11.22%$2.4M
PPBTPurple Biotech Ltd.$1.68+3.70%$2.7M
ERNAErnexa Therapeutics Inc.$1.69+0.60%$2.9M
JUNSJupiter Neurosciences Inc.$1.70-8.11%$2.2M
DRMADermata Therapeutics Inc.$0.5985-3.65%$3.0M
NRSNNeuroSense Therapeutics Ltd.$1.56-7.40%$3.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier